Biocardia Stock Analysis

BCDA -  USA Stock  

USD 1.55  0.14  8.28%

The current Biocardia price slip could raise concerns from investors as the firm is trading at a share price of 1.55 on 19,745 in volume. The company executives were unable to exploit market volatilities in April. However, diversifying your overall positions with Biocardia can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.26. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Biocardia partners.
Continue to Trending Equities.
  
Refresh
The Biocardia stock analysis report makes it easy to digest most publicly released information about Biocardia and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Biocardia Stock analysis module also helps to analyze the Biocardia price relationship with some important fundamental indicators such as market cap and management efficiency.

Biocardia Stock Analysis Notes

About 31.0% of the company shares are held by company insiders. The book value of Biocardia was currently reported as 0.8. The company recorded a loss per share of 0.76. Biocardia had not issued any dividends in recent years. The entity had a split on the 6th of June 2019. BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. Biocardia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people. For more info on Biocardia please contact Peter Altman at 650 226 0120 or go to https://www.biocardia.com.

Biocardia Quarterly Cost of Revenue

0.0

Share

Biocardia Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Biocardia's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Biocardia or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Biocardia generated a negative expected return over the last 90 days
Biocardia has high historical volatility and very poor performance
Biocardia may become a speculative penny stock
The company reported the previous year's revenue of 1.01 M. Net Loss for the year was (12.62 M) with loss before overhead, payroll, taxes, and interest of (7.54 M).
Biocardia currently holds about 12.87 M in cash with (10.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76.
Biocardia has a frail financial position based on the latest SEC disclosures
Roughly 31.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Payment of 20632 shares by David McClung of Biocardia subject to Rule 16b-3

Biocardia Upcoming and Recent Events

Earnings reports are used by Biocardia to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biocardia previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report29th of March 2022
Next Financial Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End29th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Biocardia Largest EPS Surprises

Earnings surprises can significantly impact Biocardia's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-10
2021-09-30-0.21-0.160.0523 
2021-05-13
2021-03-31-0.24-0.180.0625 
2021-03-30
2020-12-31-0.3-0.150.1550 
View All Earnings Estimates

Biocardia SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Biocardia prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Biocardia investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Biocardia specific information freely available to individual and institutional investors to make a timely investment decision.
11th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
12th of April 2022
Financial Statements and Exhibits. Other Events
View
29th of March 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
22nd of March 2022
Financial Statements and Exhibits. Other Events
View
1st of March 2022
Financial Statements and Exhibits. Other Events
View
14th of February 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Unclassified Corporate Event
View
7th of February 2022
Unclassified Corporate Event
View
3rd of February 2022
Financial Statements and Exhibits. Other Events
View

Biocardia Thematic Classifications

In addition to having Biocardia stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Biocardia Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Biocardia is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biocardia backward and forwards among themselves. Biocardia's institutional investor refers to the entity that pools money to purchase Biocardia's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Captrust Financial AdvisorsCommon Shares660.6 K1.4 M
Vanguard Group IncCommon Shares650.5 K1.3 M
Roumell Asset Management LlcCommon Shares536.5 K1.1 M
Cm Management LlcCommon Shares329 K681 K
Geode Capital Management LlcCommon Shares87.6 K181 K
Captrust Financial AdvisorsWarrants500 K151 K
Susquehanna International Group LlpCommon Shares72.3 K150 K
Commonwealth Equity Services LlcCommon Shares50 K103 K
Susquehanna International Group LlpPut Options39.7 K82 K
Susquehanna International Group LlpCall Options26.1 K54 K
Note, although Biocardia's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Biocardia Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 27.5 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biocardia's market, we take the total number of its shares issued and multiply it by Biocardia's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Biocardia Profitablity

Biocardia's profitability indicators refer to fundamental financial ratios that showcase Biocardia's ability to generate income relative to its revenue or operating costs. If, let's say, Biocardia is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Biocardia's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Biocardia's profitability requires more research than a typical breakdown of Biocardia's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.66) (0.71) 
Return on Average Equity(0.87) (0.94) 
Return on Invested Capital 7.96  8.18 
Return on Sales(12.44) (12.76) 

Management Efficiency

The entity has return on total asset (ROA) of (40.33) % which means that it has lost $40.33 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (85.43) %, meaning that it created substantial loss on money invested by shareholders. Biocardia management efficiency ratios could be used to measure how well biocardia manages its routine affairs as well as how well it operates its assets and liabilities. The current year Return on Invested Capital is expected to grow to 8.18, whereas Return on Average Assets are forecasted to decline to (0.71) . Biocardia Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 15.72 Million. The current year Current Assets is expected to grow to about 14.6 M, whereas Asset Turnover is forecasted to decline to 0.05.
Last ReportedProjected for 2022
Book Value per Share 0.61  0.63 
Enterprise Value over EBIT(1.00) (1.03) 
Enterprise Value over EBITDA(1.35) (1.39) 
Price to Book Value 3.15  4.19 
Tangible Assets Book Value per Share 0.93  0.95 
Enterprise Value17 M17.5 M
Tangible Asset Value15.7 M16 M

Technical Drivers

As of the 24th of May, Biocardia shows the Downside Deviation of 6.28, risk adjusted performance of 0.0469, and Mean Deviation of 5.22. Biocardia technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for Biocardia, which can be compared to its rivals. Please confirm Biocardia maximum drawdown, semi variance, and the relationship between the jensen alpha and potential upside to decide if Biocardia is priced correctly, providing market reflects its regular price of 1.55 per share. Please also double-check Biocardia total risk alpha, which is currently at 0.9068 to validate the company can sustain itself at a future point.

Biocardia Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Kaufman Adaptive Moving Average allows the user to define Biocardia range across which they want the smoothing.
.

Biocardia Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biocardia insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biocardia's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biocardia insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Biocardia Predictive Daily Indicators

Biocardia intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biocardia stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Biocardia Forecast Models

Biocardia time-series forecasting models is one of many Biocardia's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biocardia's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Biocardia Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biocardia stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biocardia shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Biocardia. By using and applying Biocardia Stock analysis, traders can create a robust methodology for identifying Biocardia entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(11.14) (12.02) 
Gross Margin 1.00  1.08 
Profit Margin(11.19) (12.07) 
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. Biocardia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.

Current Biocardia Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biocardia analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biocardia analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
10.33Buy3Odds
Biocardia current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Biocardia analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Biocardia stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Biocardia, talking to its executives and customers, or listening to Biocardia conference calls.
Biocardia Analyst Advice Details

Biocardia Stock Analysis Indicators

Biocardia stock analysis indicators help investors evaluate how Biocardia stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biocardia shares will generate the highest return on investment. By understating and applying Biocardia stock analysis, traders can identify Biocardia position entry and exit signals to maximize returns.
Quick Ratio3.51
Fifty Two Week Low1.1000
Revenue Growth71.70%
Shares Short Prior Month499.87k
Average Daily Volume Last 10 Day89.22k
Average Daily Volume In Three Month728.04k
Shares Percent Shares Out3.59%
Short Percent Of Float4.27%
Forward Price Earnings-2.12
Float Shares10.71M
Fifty Two Week High5.1000
Enterprise Value To Ebitda-1.19
Fifty Day Average1.7770
Two Hundred Day Average2.2889
Enterprise Value To Revenue14.76
Continue to Trending Equities. Note that the Biocardia information on this page should be used as a complementary analysis to other Biocardia's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Biocardia Stock analysis

When running Biocardia price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Is Biocardia's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine Biocardia value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.